Journal article · 2023 · Open access
Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation
Journal of the American Chemical Society, 145(25), 14155–14163 · Published 16 June 2023 · DOI 10.1021/jacs.3c05159
In brief
“Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation” is a 2023 journal article by Mengyang Chang and 5 co-authors, published in Journal of the American Chemical Society. OpenAlex counts 159 citations as of 19 November 2026, which puts it in the top 1% of works published in 2023 by citations. It is open access: the full text is free to read at PubMed Central.
- Citations
- 159
- Most cited in
- 2026 (58)
- Field-weighted impact
- 11.21
- References
- 72
- Authors
- 6
Abstract
Although proteolysis targeting chimeras (PROTACs) have become promising therapeutic modalities, important concerns exist about the potential toxicity of the approach owing to uncontrolled degradation of proteins and undesirable ligase-mediated off-target effects. Precision manipulation of degradation activity of PROTACs could minimize potential toxicity and side effects. As a result, extensive efforts have been devoted to developing cancer biomarker activating prodrugs of PROTACs. In this investigation, we developed a bioorthogonal on-demand prodrug strategy (termed c lick- r elease “ cr PROTACs”) that enables on-target activation of PROTAC prodrugs and release of PROTACs in cancer cells selectively. Inactive PROTAC prodrugs TCO-ARV-771 and TCO-DT2216 are rationally designed by conjugating a bioorthogonal trans -cyclooctenes (TCO) group into the ligand of the VHL E3 ubiquitin ligase. The tetrazine (Tz)-modified RGD peptide, c (RGDyK)-Tz, which targets integrin α v β 3 biomarker in cancer cells, serves as the activation component for click-release of the PROTAC prodrugs to achieve targeted degradation of proteins of interest (POIs) in cancer cells versus noncancerous normal cells. The results of studies accessing the viability of this strategy show that the PROTAC prodrugs are selectively activated in an integrin α v β 3 -dependent manner to produce PROTACs, which degrade POIs in cancer cells. The cr PROTAC strategy might be a general, abiotic approach to induce selective cancer cell death through the ubiquitin-proteasome pathway.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Chang, M., Gao, F., Pontigon, D., Gnawali, G. R., Xu, H., & Wang, W. (2023). Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation. Journal of the American Chemical Society, 145(25), 14155–14163. https://doi.org/10.1021/jacs.3c05159
MLA 9
Chang, Mengyang, et al. “Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation.” Journal of the American Chemical Society, vol. 145, no. 25, 2023, pp. 14155–14163. https://doi.org/10.1021/jacs.3c05159.
Chicago
Chang, Mengyang, Feng Gao, Devin Pontigon, Giri Raj Gnawali, Hang Xu, and Wei Wang. 2023. “Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation.” Journal of the American Chemical Society 145 (25): 14155–14163. https://doi.org/10.1021/jacs.3c05159.
Harvard
Chang, M. et al. (2023) ‘Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation’, Journal of the American Chemical Society, 145(25), pp. 14155–14163. doi:10.1021/jacs.3c05159.
IEEE
M. Chang, F. Gao, D. Pontigon, G. R. Gnawali, H. Xu, and W. Wang, “Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation,” Journal of the American Chemical Society, vol. 145, no. 25, pp. 14155–14163, 2023, doi: 10.1021/jacs.3c05159.
BibTeX
@article{chang2023bioorthogonal,
title = {{Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation}},
author = {Chang, Mengyang and Gao, Feng and Pontigon, Devin and Gnawali, Giri Raj and Xu, Hang and Wang, Wei},
journal = {Journal of the American Chemical Society},
year = {2023},
volume = {145},
number = {25},
pages = {14155--14163},
doi = {10.1021/jacs.3c05159},
url = {https://doi.org/10.1021/jacs.3c05159}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2023 | 12 | |
| 2024 | 37 | |
| 2025 | 52 | |
| 2026 | 58 |
Its field-weighted citation impact is 11.21: it has been cited 11.21 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- PROTACs
- trans-cyclooctene
- VHL E3 ubiquitin ligase
- tetrazine
- RGD peptide
- integrin αvβ3
- targeted protein degradation
- ubiquitin-proteasome system
Work with this paper
Most-cited papers in Biochemistry, Genetics and Molecular Biology
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTOliver H. Lowry, NiraJ. Rosebrough, A. Lewis Farr and 1 more · Journal of Biological Chemistry · 1951 · 316,470 citations
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingM Bradford · Analytical Biochemistry · 1976 · 256,780 citations
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodKenneth J. Livak, Thomas D. Schmittgen · Methods · 2001 · 184,418 citations
- Molecular Cloning: A Laboratory ManualJoseph Sambrook, Elisabeth Fritsch, Tom Maniatis · UCLA - Biblioteca de Ciencias de la Salud · 1989 · 133,493 citations
- Basic Local Alignment Search ToolStephen F. Altschul, Warren R. Gish, Webb Miller and 2 more · Journal of Molecular Biology · 1990 · 100,529 citations
All highly cited Biochemistry, Genetics and Molecular Biology papers
Questions about this paper
How do I cite this paper in APA style?
Chang, M., Gao, F., Pontigon, D., Gnawali, G. R., Xu, H., & Wang, W. (2023). Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation. Journal of the American Chemical Society, 145(25), 14155–14163. https://doi.org/10.1021/jacs.3c05159
How many times has this paper been cited?
159 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at PubMed Central: sign in and open the PDF from this page.
Who wrote this paper?
Mengyang Chang, Feng Gao, Devin Pontigon, Giri Raj Gnawali, Hang Xu, Wei Wang.
What is the DOI of this paper?
10.1021/jacs.3c05159, permanently at https://doi.org/10.1021/jacs.3c05159. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.